PPI

19 Drugs classified under this drug class

PPI. Pantoprazole 20 mg.
E.C. TABS: 30. Adult. & adolesc. 12 yrs. of
age and above: Reflux dis. and assoc.
symp. (e.g. heartburn, acid
regurgitation, pain on swallowi.)-
20mg×1/d. Symp. relief is gener.
accompl. within 2-4 wks. If this is not
suffic., symp. relief will normal. be
achieved within a further 4 wks. When
symp. relief has been achieved,
reoccurring symp. can be control. using
an on-demand regimen of 20mg×1/d,
taking one tab. when requir.
Long-term manag.& preven. of relapse
in reflux esophag.: Mainten. dose- is 20
mg×1/d is recomm., incr. to 40 mg ×1/d
if a relapse occurs.After heal. of the
relapse the dose can be reduced again
to 20 mg.
Adults: Preven. of gastroduod. ulc.
induced by NSAIDs in pts. at risk with a
need for contin. NSAID tmt.:
20mg×1/d.
Tmt. of reflux esophagitis & assoc. symp.
(e.g. heartburn, acid regurgitation, pain
on swallow.). For long-term manag. &
prevent. of relapse in reflux esophagitis.
Preven. of gastroduodenal ulc. induced
by NSAIDs in pts. at risk with a need for
continuous NSAIDs tmt.
C/I: Hypersens., subst. benzimidazoles. Comb. ther. for the eradication of H. pylori in pts. with renal impair. or severe hep. impair.

PPI. Pantoprazole 40 mg.
E.C. TABS: 14, 28. Tmt. mod-severe
GERD: Adults/adolesc. 12 yrs and
above: 1 tab x dly. Erad. H. pylori in
comb. with 2 approp. antibiotics:
Adults: Depend. On resist. pattern: a) 2
x dly: 1 x 40 mg +1,000 mg amoxillin +
500 mg clarithromycin; b) 2 x dly: 1 x
40 mg + 500 mg metronidazole + 500
mg clarithromycin; c) 2 x dly: 1 x 40 mg
+ 1,000 mg amoxicillin + 500 mg
metronidazole. If comb. ther. not an
option: Monother. as follows: Tmt.
gastric/duod. ulc: 1 tab dly.
Zollinger-Ellison syndr. + other
hypersecret. conds: Long-term
manage: Initial: 80 mg dly. Can titrate
up/ down as reqd. Doses above 80 mg
dly to be div. into 2 doses.
Pts. with hep. impair.: dly. dose of 20
mg exceed. in pts. with sev. hep.
impair, must not be used in comb. tmt.
For eradic. H. pylori in pts. with moder.
– sev. hep. dysfunc. since curren. no
data are availab. on the effic. & safety
of Pantoprazole in comb. tmt. of these
pts. 
Short term tmt. of acute duod. ulcer,
acute gastric ulcer, mod./sev. reflux
esophagi., eradic. of H. pylori in comb.
With clarithromycin and amoxycillin
orclarithromycin and metronidazole or
amoxicillin and metronidazole in cases of
duoden. ulcer & gastric ulcer with the
object. of reduc. of duod./gastr.ulc.
caused by this microorganism, Zollinger
Ellison Syndr.
C/I: Hypersens., subst. benzimidazoles .
Comb. ther. for the eradication of H.
pylori in pts. with renal impair. or severe
hep. impair..

PPI. Pantoprazole (as sodium) 40 mg/vial.
VIAL: 1. Duodenal ulcer, gastric ulc., moderate and severe reflux oesophagitis: 40 mg (1 vial) ×1/d.
Zollinger-Ellison-Syndr.: For the long-term manag. of Zollinger-Ellison-Syndr. pts. should start their tmt. with a dly. dose of 80 mg. Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secret. to guide. With doses above 80 mg dly., the dose should be divided and given twice dly. A temporary incr. of the dose above 160 mg  is possible but should not be applied longer than requir. for adequate. acid control.
In case a rapid acid control is requir, a start. dose of 80 mg×2/d. is suffic. to manage a decrease of acid output into the target range (<10 mEq/h) within 1h in the majority of pts.
Duodenal ulcer. Gastric ulcer. Moderate and severe reflux oesophagitis. Zollinger-Ellison-Syndrome.
C/I: Hypersens. to the active subst., substitut. benzimidazoles and any of the excipients.

PPI. Esomeprazole 20 mg, Esomeprazole 40 mg.
Tab. 20 mg X  7/14/28/50, 40 mg X  7/14/28/50s
Erosive reflux esophagitis; prolonged tmt. after i.v. induced prevent. of rebleeding of peptic ulcer assoc. with NSAIDS ther. .;  40 mg 1 X dly for 4 weeks.
long-term managem. of pts. with healed esophagitis to prev. relapse; symptom. tmt. of gastroesophageal reflux disease (GERD) ; prevent. of gastric and duodenal ulcers associated with NSAID ther. in patients at risk:  20 mg X1 dly. In combin. with an appropr. antibact. ther. for eradic. of Helicobacter pylori: 20 mg X2 dly. Doses for adolesc. are the same as for adults.
Adults for:. GERD- tmt. of erosive reflux esophagitis- long-term managem. of pts. with healed esophagitis to prev. relapse- symptom. tmt. GERD. In comb. with an appropr. antibact. therap. for eradication of Helicobacter pylori and:- healing of Helicobacter pylori assoc. duodenal ulcer and- prevent. of relapse of peptic ulcers in pts. with Helicobacter pylori assoc. ulcers. Pts. req. NSAID ther.- healing of gastr. ulcers assoc. with NSAID ther. – prevent. of gastr. and duodenal ulcers assoc. with NSAID ther. in pts. at risk. Prolong. tmt. after i.v. induced prevent. of rebleed. of peptic ulcers. In adolesc. from the age of 12 years for GERD (only with 20 mg)- tmt. of erosive reflux esophagitis- long-term managem. of pts. with healed esophagitis to prevent relapse- symptom. tmt. of GERD. In combin. with antibiot. in tmt. of duodenal ulcer caused by Helicobacter pylori.
C/I:  hypersens. to esomeprazole, substit. benzimidazoles or any other constit. Not to be administr. with nelfinavir

PPI. Esomeprazole 40 mg.
Vial. Powd. for infus./inject. 50X 40 mg
Adults:20-40 mg 1 X dly. Transfer to oral ther. asap.  GERD with esophagitis: 40 mg 1 X dly. Sympt. tmt. GERD: 20 mg 1 X dly. All as IV, as altern. to oral ther. when oral intake not appropr. Prevent. of rebleed. follow. therap. endoscopy for acute bleed. gastric/duoden. ulcers: 80 mg as a bolus, contin. by 8 mg/h given over 3 days.
Chldr. aged 1-11: 10 mg 1 X dly. Chldr. aged 12-18: 20 mg 1X dly. See prescr. info.
 In  adlts. for: Gastroesophageal reflux disease (GERD) in pts. with esophagitis and/or sev. sympt. of reflux as an altern. to oral ther. when oral intake is not appropr / Prevent. of rebleed. follow therap. endoscopy for ac. bleeding gastric or duodenal ulcers.
In child. and adolesc. aged 1-18 years for:  Gastric antisecret. tmt. when oral route is not possible, such as GERD in pts. with erosive reflux esophagitis and/or sev. sympt. of reflux.  
C/I:  :  hypersens. to esomeprazole, substit. benzimidazoles or any other constit. Not to be administr. with nelfinavir